Skip to main content

Advertisement

Table 1 Characteristics of clinical trials published in the 10 highest-impact US medical specialty society journals between 1 January 2010 and 31 December 2015 (N = 486)

From: Adherence to the International Committee of Medical Journal Editors’ (ICMJE) prospective registration policy and implications for outcome integrity: a cross-sectional analysis of trials published in high-impact specialty society journals

  Number Percentage
Interventiona
 Drug 287 59.1
 Device 46 9.5
 Vaccine or biological 86 17.7
 Other 102 21.0
Phaseb
 Phase II 190 39.1
 Phase III 110 22.6
 Phase IV 46 9.5
 Not listed 153 31.5
Randomization
 Yes 372 76.5
 No 114 23.5
Fundingc, d
 Industry 216 44.4
 Non-industry 270 55.6
Enrollment
  ≥ 100 280 57.6
  < 100 206 42.4
Location(s)
 US only 166 34.2
 US and international 84 17.3
 International only 236 48.6
Trial registrye
 ClinicalTrials.gov 383 87.2
 EU-CTR 76 17.3
 ISRCTN 24 5.5
 Other registriesf 47 10.7
  1. aClinical trials may have involved more than one intervention type
  2. b13 trials were designated as phase II/phase III
  3. cFunding information was not reported in the publications of 5 trials, all of which were unregistered; these trials were designated as not reporting industry funding
  4. dIndustry funding includes partial or full support
  5. e439 trials were registered. Percentages are expressed based on a denominator of 439. 81 trials were registered in multiple registries, hence percentages may not sum to 100
  6. f“Other registries” includes: Australia New Zealand Clinical Trials Register (ANZCTR), Chinese Clinical Trial Registry (ChiCTR), Clinical Trial Registry of India (CTRI), German Clinical Trials Register (DRKS), Japan Pharmaceutical Information Center Clinical Trials Information (JAPIC-CTI), Netherlands Trial Register (NTR), University Hospital Medical Information Network (UMIN) (a Japanese registry)
  7. Abbreviations: EU-CTR European Union Clinical Trials Register, ISRCTN International Standard Randomized Controlled Trial Network